Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Heart Fail Rev ; 27(2): 455-464, 2022 03.
Article in English | MEDLINE | ID: mdl-33682033

ABSTRACT

Previous primary studies have explored the association between blood pressure (BP) and mortality in ambulatory heart failure (HF) patients reporting varying and contrasting associations. The aim is to determine the pooled BP prognostic value and explore potential reasons for between-study inconsistency. We searched Medline, Cochrane, EMBASE and CINAHL from January 2005 to October 2018 for studies with ≥ 50 events (mortality and/or hospitalization) and included BP in a multivariable model in ambulatory HF patients. We pooled hazard ratios (random effects model) for systolic BP (SBP) or diastolic BP (DBP) effect on mortality and/or hospitalization risk. We used a priori defined sub-group analyses to explore heterogeneity and GRADE approach to assess the certainty of the evidence. Seventy-one eligible articles (239,467 screened) at low to moderate risk of bias included 235,752 participants. Higher SBP was associated with reduced all-cause mortality (HR 0.93, 95%CI 0.91-0.95, I2 = 87.13%, moderate certainty), all-cause hospitalization events (HR 0.91, 95%CI 0.88-0.93, I2 = 44.4%, high certainty) and their composite endpoint (HR 0.93 per 10 mmHg, 95%CI 0.91-0.94, I2 = 86.3%, high certainty). DBP did not demonstrate a statistically significant effect for all outcomes. The association strength was significantly weaker in studies following patients with either LVEF > 40%, higher average SBP (> 130 mmHg), increasing age and diabetes. All other a priori subgroup hypotheses did not explain between study differences. Higher ambulatory SBP is associated with reduced risk of all-cause mortality and hospitalization. Patients with lower BP and reduced LVEF are in a high-risk group of developing adverse events with moderate certainty of evidence.


Subject(s)
Heart Failure , Hypertension , Blood Pressure/physiology , Blood Pressure Monitoring, Ambulatory , Humans , Prognosis
2.
BMC Health Serv Res ; 20(1): 370, 2020 May 01.
Article in English | MEDLINE | ID: mdl-32357891

ABSTRACT

BACKGROUND: The 2013 Diabetes Canada guidelines recommended routinely using vascular protective medications for most patients with diabetes. These medications included statins and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Antiplatelet agents were only recommended for secondary prevention of cardiovascular disease. Using Electronic Medical Record (EMR) data, we previously found that guideline dissemination efforts were not associated with an increase in the rate of primary care prescriptions of these medications. However, this needs confirmation: patients can receive prescriptions from different sources including specialists and they may not always fill these prescriptions. Using both EMR and administrative health data, we examined whether guideline dissemination impacted the dispensing of vascular protective medications to patients. METHODS: The study population included patients with diabetes aged 66 or over in Ontario, Canada. We created two cohorts using two different approaches: an Electronic Medical Record (EMR) algorithm for diabetes using linked EMR-administrative data and an administrative algorithm using population level administrative data. We examined data from January 2010 to December 2016. Patients with diabetes were deemed to be likely taking a medication (or covered) during a quarter if the daily amount for a dispensed medication would last for at least 75% of days in any given quarter. An interrupted time series analysis was used to assess the proportion of patients covered by each medication class. Proton pump inhibitors (PPIs) were used as a reference. RESULTS: There was no increase in the rate of change for medication coverage following guideline release in either the EMR or the administrative diabetes cohorts. For statins, the change in trend was - 0.03, p = 0.7 (EMR) and - 0.12, p = 0.04(administrative). For ACEI/ARBs, this was 0.03, p = 0.6 (EMR) and 0, p = 1(administrative). For antiplatelets, this was 0.001, P = .97 (EMR) and - 0.03, p = 0.03 (administrative). The comparator PPI was - 0.07, p = 0.4 (EMR) and - 0.11, p = 0.002 (administrative). CONCLUSIONS: Using both EMR and administrative health data, we confirmed that the Diabetes Canada 2013 guideline dissemination strategy did not lead to an increased rate of coverage for vascular protective medications. Alternative strategies are needed to effect change in practice.


Subject(s)
Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Diabetes Mellitus/drug therapy , Drug Prescriptions/statistics & numerical data , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Practice Guidelines as Topic , Aged , Aged, 80 and over , Cohort Studies , Databases, Factual , Electronic Health Records , Female , Humans , Male , Ontario , Primary Health Care
3.
Ann Clin Psychiatry ; 31(2): 111-122, 2019 05.
Article in English | MEDLINE | ID: mdl-31046032

ABSTRACT

BACKGROUND: The clustering of sleep alterations, cardiometabolic risk, and depressive symptoms suggests a convergence in their pathophysiology. We quantify the role of depressive symptoms in mediating the association between empirically derived sleep indices and body mass index (BMI). METHODS: Data were derived from 8,844 adult participants of the 2005 to 2008 US National Health and Nutrition Examination Survey. Factor analysis of the Sleep Disorders Questionnaire was conducted. Ordinary least squares path analysis quantified the effects of sleep indices on BMI directly and indirectly via depressive symptom severity (ie, Patient Health Questionnaire). RESULTS: Three sleep indices were extracted: poor sleep-related functional impairment, sleep disturbance, and daytime sleepiness. The associations between functional impairment, sleep disturbance, and daytime sleepiness and BMI were mediated by the effects of sleep on depressive symptoms (κ2 = 0.02) after adjustment for covariates. Daytime sleepiness was associated with BMI independent of depressive symptoms, whereas poor sleep-related functional impairment and sleep disturbance were not. CONCLUSIONS: Higher subjective ratings of sleep-related functional impairment, sleep disturbance, or daytime sleepiness indirectly increased BMI by worsening overall depressive symptom severity. A testable hypothesis is whether preemptive targeting of depressive symptoms in populations with sleep disturbances may decrease risk for obesity and other concurrent metabolic comorbidities.


Subject(s)
Depression/physiopathology , Obesity/epidemiology , Severity of Illness Index , Sleep Wake Disorders/epidemiology , Body Mass Index , Comorbidity , Depression/epidemiology , Female , Humans , Male , Middle Aged , Nutrition Surveys , Psychiatric Status Rating Scales , Surveys and Questionnaires , United States/epidemiology
4.
J Card Surg ; 28(5): 604-10, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23844652

ABSTRACT

BACKGROUND: The HeartWare ventricular assist device (HVAD) is a new generation centrifugal flow VAD recently introduced in Canada. The objective of this study was to compare the HVAD device to the HeartMate II (HMII) axial flow device. Very few studies have compared clinical outcomes between newer generation VADs. METHODS: All perioperative and follow-up data on LVAD recipients were collected prospectively in our institutional database. Between January 2006 and April 2012, 46 consecutive patients underwent implantation of either an HVAD (n=13) or a HMII (n=33) device. Pre-implant demographics, perioperative and postoperative clinical outcomes were reviewed between groups. RESULTS: Overall, the baseline characteristics, demographics, co-morbidities and laboratory values were comparable between the two groups. The majority of the patients were Interagency Registry for Mechanical Assisted Circulatory Support 3-4 (92% in both groups) and most of the patients were bridge to transplant (75% in HMII vs. 79% in HVAD). Survival and the incidence of perioperative bleeding, renal dysfunction, liver dysfunction, and infection were similar between the groups. However, HVAD devices had a significantly higher incidence of gastrointestinal (GI) bleeding (31% vs. 0% in HMII patients, p<0.01) and stroke (44% vs. 10% in HMII patients, at one year p=0.04). Hemorrhagic strokes were more frequent in patients with HVAD (three of the five episodes vs. one of the three episodes in HMII patients, p=0.06). CONCLUSION: While device complications were comparable, patients with HVAD experienced a significantly higher incidence of stroke and GI bleeding and therefore refinement in patients' management may decrease incidence of these complications.


Subject(s)
Cerebral Hemorrhage/epidemiology , Cerebral Hemorrhage/etiology , Gastrointestinal Hemorrhage/epidemiology , Gastrointestinal Hemorrhage/etiology , Heart-Assist Devices , Stroke/epidemiology , Stroke/etiology , Adult , Aged , Cohort Studies , Female , Heart-Assist Devices/adverse effects , Humans , Incidence , Male , Middle Aged , Prospective Studies , Retrospective Studies
5.
J Heart Lung Transplant ; 41(7): 937-951, 2022 07.
Article in English | MEDLINE | ID: mdl-35570129

ABSTRACT

BACKGROUND: Prognostic factors in lung transplantation are those variables that are associated with transplant outcomes. Knowledge of donor and recipient prognostic variables can aid in the optimal allocation of donor lungs to transplant recipients and can also inform post-operative discussions with patients about prognosis. Current research findings related to prognostic factors in lung transplantation are inconsistent and the relative importance of various factors is unclear. This review aims to provide the best possible estimates of the association between putative prognostic variables and 1-year all-cause mortality in adult lung transplant recipients. METHODS: We searched 5 bibliographic databases for studies assessing the associations between putative predictors (related to lung donors, recipients, or the transplant procedure) and 1-year recipient mortality. We pooled data across studies when justified and utilized GRADE methodology to assess the certainty in the evidence. RESULTS: From 72 eligible studies (2002-2020), there were 34 recipient variables, 4 donor variables, 10 procedural variables, and 7 post-transplant complication variables that were amenable to a meta-analysis. With a high degree of certainty in the evidence only post-transplant need for extra-corporeal membrane oxygenation (ECMO) (HR 1.91, 95% CI 1.79-2.04) predicted 1-year mortality. No donor variables appeared to predict transplant outcome with high or even moderate certainty. CONCLUSION: Across the range of contemporary donors and recipients that clinicians accept for lung transplantation, this review, with high certainty, found 1 prognostic factor that predicted 1-year mortality, and 37 additional factors with a moderate degree of certainty. The lack of prognostic significance for some widely accepted factors (e.g., donor smoking, age) likely relates to existing limits in the range of these variables at the time of donor and recipient selection.


Subject(s)
Lung Transplantation , Adult , Humans , Postoperative Complications , Prognosis , Retrospective Studies , Tissue Donors , Transplant Recipients
6.
Diabetes Care ; 42(1): 148-156, 2019 01.
Article in English | MEDLINE | ID: mdl-30389671

ABSTRACT

OBJECTIVE: The 2013 Diabetes Canada guidelines launched targeted dissemination tools and a simple assessment for vascular protection. We aimed to 1) examine changes associated with the launch of the 2013 guidelines and additional dissemination efforts in the rates of vascular protective medications prescribed in primary care for older patients with diabetes and 2) examine differences in the rates of prescriptions of vascular protective medications by patient and provider characteristics. RESEARCH DESIGN AND METHODS: The study population included patients (≥40 years of age) from the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) with type 2 diabetes and at least one clinic visit from April 2010 to December 2015. An interrupted time series analysis was used to assess the proportion of eligible patients prescribed a statin, ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB), or antiplatelet prescription in each quarter. Proton pump inhibitor (PPI) prescriptions were the reference control. RESULTS: A dynamic cohort was used where participants were enrolled each quarter using a prespecified set of conditions (range 25,985-70,693 per quarter). There were no significant changes in statin (P = 0.43), ACEI/ARB (P = 0.42), antiplatelet (P = 0.39), or PPI (P = 0.16) prescriptions at baseline (guideline intervention). After guideline publication, there was a significant change in slope for statin (-0.52% per quarter, SE 0.15, P < 0.05), ACEI/ARB (-0.38% per quarter, SE 0.13, P < 0.05), and reference PPI (-0.18% per quarter, SE 0.05, P < 0.05) prescriptions. CONCLUSIONS: There was a decrease in prescribing trends over time that was not specific to vascular protective medications. More effective knowledge translation strategies are needed to improve vascular protection in diabetes in order for patients to receive the most effective interventions.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Drug Prescriptions , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Adult , Aged , Aged, 80 and over , Canada , Cross-Sectional Studies , Female , Humans , Interrupted Time Series Analysis , Male , Middle Aged , Practice Guidelines as Topic , Proton Pump Inhibitors/therapeutic use , Retrospective Studies , Treatment Outcome
7.
BMC Obes ; 5: 32, 2018.
Article in English | MEDLINE | ID: mdl-30524737

ABSTRACT

BACKGROUND: The relationship between obesity and depression is complex. This study assessed the impact of body mass index (BMI) on the link between BMI, inflammation, oxidative stress, sleep quality and self-reported depressive symptoms. METHODS: We used data from the U.S. National Health and Nutritional Examination Survey 2005-2008 cycles (n = 9133; ≥20y). Depressive symptoms and sleep quality were determined from questionnaires. C-reactive Protein (CRP) was used as a biomarker of inflammation and γ-glutamyltransferase was used to assess oxidative stress. The relationship between depressive symptoms, sleep quality, and biomarkers were assessed with regression models. The moderating effects of BMI and sex were tested. RESULTS: BMI was a significant moderator of the relationship between γ-glutamyltransferase and depressive symptoms (p = 0.02), but not CRP or sleep quality. Higher BMI increased odds of depressive symptoms in women (OR (95% CI): 3.92 (1.85-8.30) for BMI ≥25 to < 30 kg/m2; 3.17 (1.53-6.58) for BMI ≥30 to < 35 kg/m2; and 7.38 (2.11-25.76) for BMI ≥35 kg/m2). BMI was also a significant moderator of γ-glutamyltransferase levels in those with vs without depressive symptoms. Those with depressive symptoms had 24% poorer sleep quality compared to those without depressive symptoms after adjusting for inflammation, oxidative stress and other confounders. CONCLUSIONS: The link between oxidative stress and depressive symptoms may be particularly relevant for females and people living with obesity. People with depressive symptoms also have a substantial reduction in sleep quality. Thus, research should examine these relationships prospectively to inform and improve the mental health of the adult population in developed countries.

8.
Can J Public Health ; 106(5): e283-9, 2015 Apr 30.
Article in English | MEDLINE | ID: mdl-26451989

ABSTRACT

OBJECTIVES: This research examines the feasibility of using electronic medical records within the Canadian Primary Care Sentinel Surveillance Network (CPCSSN) for obesity surveillance in Canada by assessing obesity trends over time and comparing BMI distribution estimates from CPCSSN to those obtained from nationally representative surveys. METHODS: Data from 2003-2012 on patients 18 years and older (n = 216,075) were extracted from the CPCSSN database. Patient information included demographics (age and sex) and anthropometric measures (height, weight, body mass index (BMI), waist circumference, and waist-to-hip ratio). Standard descriptive statistics were used to characterize the sample, including, as appropriate, means, proportions and medians. The BMI distribution of the CPCSSN population was compared to estimates from the Canadian Community Health Survey (CCHS) and the Canadian Health Measures Survey (CHMS) for the years: 2004, 2007-2009 and 2009-2011. RESULTS: The estimated prevalence of obesity increased from 17.9% in 2003 to 30.8% in 2012. Obesity class I, II and III prevalence estimates from CPCSSN in 2009-2011 (18.0%, 95% CI: 17.8-18; 7.4%, 95% CI: 7.3-7.6; 4.2%, 95% CI: 4.1-4.3 respectively) were greater than those from the most recent (2009- 2011) cycle of the CHMS (16.2%, 95% CI: 14-18.7; 6.3%, 95% CI: 4.6-8.5; 3.7%, 95% CI: 2.8-4.8 respectively), however these differences were not statistically significant. CONCLUSION: The data from CPCSSN present a unique opportunity for longitudinal obesity surveillance among primary care users in Canada, and offer prevalence estimates similar to those obtained from nationally representative survey data.


Subject(s)
Electronic Health Records , Obesity/epidemiology , Primary Health Care , Sentinel Surveillance , Adolescent , Adult , Aged , Body Mass Index , Canada/epidemiology , Feasibility Studies , Female , Health Surveys , Humans , Male , Middle Aged , Prevalence , Reproducibility of Results , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL